KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Debt (2016 - 2020)

Nektar Therapeutics (NKTR) has 10 years of Total Debt data on record, last reported at $508.9 million in Q1 2020.

  • For Q1 2020, Total Debt rose 105.73% year-over-year to $508.9 million; the TTM value through Mar 2020 reached $508.9 million, up 105.73%, while the annual FY2019 figure was $502.9 million, 103.64% up from the prior year.
  • Total Debt reached $508.9 million in Q1 2020 per NKTR's latest filing, up from $502.9 million in the prior quarter.
  • Across five years, Total Debt topped out at $508.9 million in Q1 2020 and bottomed at $242.1 million in Q1 2016.
  • Average Total Debt over 5 years is $275.9 million, with a median of $245.6 million recorded in 2018.
  • Peak YoY movement for Total Debt: grew 0.71% in 2019, then skyrocketed 105.73% in 2020.
  • A 5-year view of Total Debt shows it stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then surged by 103.64% to $502.9 million in 2019, then rose by 1.2% to $508.9 million in 2020.
  • Per Business Quant database, its latest 3 readings for Total Debt were $508.9 million in Q1 2020, $502.9 million in Q4 2019, and $248.3 million in Q3 2019.